11 clinical trials found.
-
A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of TRQ15-01 administered i.v. in patients with relapsed/refractory metastatic ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER
If you have been diagnosed with locally advanced or metastatic (the spread of) melanoma, locally advanced or metastatic (the spread of) urothelial bladder cancer or ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
If you have been diagnosed with a rare cancer or a rare cancer of unknown primary origin, you may qualify for this study. The main ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
If you have been diagnosed with solid tumors, either removed previously by surgery or unresectable (locally advanced or metastatic), you may qualify for this phase ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1 Open-Label Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety Tolerability Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Ad
If you have been diagnosed with advanced malignancies, an advanced form of cancer, you may be qualified to participate in this Phase I study evaluating ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase I/IIa Study of BMS-986205 Administered in Combination with Nivolumab (BMS-935558 anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
If you have been diagnosed with advanced(metastatic (spread to another area of the body) and/or unresectable (cannot be removed from the body)) malignant tumors, including ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase I Open Label Study of GSK3359609 Administered alone in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors
If you have been diagnosed with selected advanced or recurrent solid tumors including bladder cancer, cervical cancer, colorectal cancer, esophageal cancer with squamous cell ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
An open-label dose-finding and proof of concept study for Probody Therapeutics (Probody Tx) in subjects with metastatic or locally advanced unrespectable solid tumors and/or lymphomas
If you have been diagnosed with a metastatic or advanced unresectable solid tumor or lymphoma, you may qualify for this study evaluating the investigational drug ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1 Open-Label Study of the Safety Tolerability and Efficacy of KPT-9274 A Dual Inhibitor of PAK4 and NAMPT in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma (PANAMA)
if you are newly diagnosed with non-Hodgkin's lymphoma or advanced solid malignancies, you may qualify to participate in a clinical trial. The main goal ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A PHASE Ib MULTICENTER OPEN-LABEL STUDY TO EVALUATE THE SAFETY EFFICACY AND PHARMAKOKINETICS OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION
The purpose of this study is to explore the effects, good or bad, of cibisatamab, atezolizumab, obinutuzumab, and tocilizumab on patients with CRC. In this ...
Phase
Interventional
TRIAL ROLE: Co-Investigator
